期刊文献+

艾滋病暴露前预防的研究进展 被引量:6

Research progress in pre-exposure prophylaxis of HIV transmission
原文传递
导出
摘要 全球艾滋病新发感染依然严峻,干预策略仍然不能普遍有效,亟需新的高效的干预措施整合到生物医学预防-行为预防-社会结构预防的综合模式当中,如暴露前预防。猕猴和小鼠模型证明了它的有效性和安全性,但结果仅限于指导临床试验的设计,因为只有临床试验才能真正说明暴露前预防能否有效阻断艾滋病传播。该策略成功的关键因素有两点:一是个人风险决策;二是社会环境易感性。暴露前预防在艾滋病领域拥有巨大潜能,需要及早纳入计划并拟定相关的应急方案。 In the context of worldwide increasing new cases of HIV infection and less optimistic intervention strategies,it will be essential to develop new,highly effective integrated interventions to combine with biomedical,behavioral and social prevention.Preclinical researches in animal models of macaques and mice have proved the efficacy and safety of pre-exposure prophylaxis(PrEP),however they remain at a stage of guiding the design of clinical trails and only the result of clinical trails may ultimately determine if PrEP can truly interrupt HIV transmission.Not only personal risk strategy for HIV infection,but also social and environmental vulnerability will be key to successful PrEP programs.PrEP has great potential in the area of HIV prevention and requires early planning and comprehensive implementation.
出处 《中国艾滋病性病》 CAS 2010年第6期622-625,共4页 Chinese Journal of Aids & STD
关键词 暴露前预防 性传播感染 艾滋病生物医学预防 Pre-exposure prophylaxis Sexually transmitted infection Biomedical HIV prevention
  • 相关文献

参考文献38

  • 1UNAID, WHO. 2009 AIDS epidemic update[EOL]. 2009 Nov. available at : http://www, unaids, org/en/KnowledgeCentre/ HIVData/EpiUpdate/EpiUpdArchive/2009/.
  • 2Horton R, Das P. Putting prevention at the forefront of HIV/ AIDS[J]. Lancet,2008, 372(9637): 421-422.
  • 3Thomas C. Roadblocks in HIV research: five questions[J]. Nat Meal,2009, 15(8): 855-859.
  • 4White RG, Glynn JR, Orroth KK et al. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? [J].AIDS,2008, 22(14): 1841-1850.
  • 5Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and recta-analysis [J]. Lancet Infect Dis,2009, 9(11): 669-677.
  • 6Wang L, Wang N, Li D et al. The 2007 Estimates for People at Risk for and Living With HIV in China: Progress and Challenges [J]. J Acquir Immune Defic Syndr,2009, 50(4): 414-418.
  • 7Derdelinckx I, Wainberg MA, Lange JM et al. Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection[J]. PLoS Med,2006, 3(11): e454.
  • 8Imrie J, Elford J, Kippax S et al. Biomedical HIV prevention-and social science[J]. Lancet,2007, 370(9581): 10--11.
  • 9Paltiel AD, Freedberg KA, Scott CA et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost effectiveness[J]. Clin Infect Dis,2009, 48(6), 806--815.
  • 10Gilead Sciences, Inc. highlights of prescribing information [OL]. 2008 Nov. avilable at : http://www, gilead, com/pdf/ viread_pi, pdf.

同被引文献97

引证文献6

二级引证文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部